Peer-reviewed veterinary case report
Rescue chemotherapy for resistant lymphoma in cats
By Martin, Olya A & Price, Josh·Published in Journal of feline medicine and surgery·2018·1 Department of Small Animal Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Mechlorethamine, vincristine, melphalan and prednisolone rescue chemotherapy protocol for resistant feline lymphoma.
- Species:
- cat
Plain-English summary
A group of 12 cats with resistant lymphoma (a type of cancer) received a combination of chemotherapy drugs called MOMP (mechlorethamine, vincristine, melphalan, and prednisolone) to see if it could help them. Out of these cats, 7 showed a positive response to the treatment, with 3 achieving complete remission and 4 showing partial improvement. The treatment was generally safe, with mild side effects like low white blood cell counts in some cats, but no one needed to be hospitalized. Overall, MOMP proved to be an effective option for cats struggling with this challenging condition.
People also search for: cat lymphoma treatment · feline cancer chemotherapy · side effects of chemotherapy in cats
Abstract
Objectives The goals of this retrospective study were to evaluate the use of mechlorethamine, vincristine, melphalan and prednisolone (MOMP) chemotherapy for rescue of feline lymphoma, to describe the protocol's toxicity and to determine prognostic indicators for progression-free survival. Methods The medical records of 12 cats treated with MOMP chemotherapy at the University of Tennessee Veterinary Medical Center between 2007 and 2017 were evaluated. Parameters assessed included lymphoma cell size, anatomical location, number of previous chemotherapy drugs and number of previous rescue protocols received. Chemotherapy-related toxicity was also described. Results Seven of 12 cats responded to this rescue protocol. Three cats experienced complete response and four cats achieved partial response for a median duration of 39 days (range 14-345 days). Cats that achieved complete response had a significantly longer median progression-free survival than cats that did not respond to treatment. Five of 12 cats developed hematologic toxicity (neutropenia) and one cat developed gastrointestinal toxicity. Toxicity was mild in most cases; no cats needed to be hospitalized. Neutropenia was associated with increased progression-free survival. Conclusions and relevance MOMP is a safe and effective rescue chemotherapy protocol for cats with relapsing and refractory lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29065803/